Interestingly, SBF-1 was also able to overcome the resistance of CRC to the anti-VEGF therapy with bevacizumab by interfering mitochondrial HIBCH, which can be used as a new combined therapy for CRC. The gene discussed is VEGFA; the disease is colorectal carcinoma.